ADMA Biologics, Inc. (ADMA)
9.62
+0.04
(+0.42%)
USD |
NASDAQ |
Sep 04, 16:00
9.52
-0.10
(-1.04%)
After-Hours: 20:00
ADMA Biologics Research and Development Expense (Quarterly) : 6.014M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 6.014M |
| March 31, 2026 | 2.597M |
| December 31, 2025 | 1.376M |
| September 30, 2025 | 1.528M |
| June 30, 2025 | 1.031M |
| March 31, 2025 | 0.826M |
| December 31, 2024 | 0.391M |
| September 30, 2024 | 0.412M |
| June 30, 2024 | 0.56M |
| March 31, 2024 | 0.45M |
| December 31, 2023 | 0.4455M |
| September 30, 2023 | 0.5959M |
| June 30, 2023 | 1.403M |
| March 31, 2023 | 0.8554M |
| December 31, 2022 | 1.074M |
| September 30, 2022 | 1.042M |
| June 30, 2022 | 0.8734M |
| March 31, 2022 | 0.6241M |
| December 31, 2021 | 0.729M |
| September 30, 2021 | 0.7706M |
| June 30, 2021 | 1.159M |
| March 31, 2021 | 0.9876M |
| December 31, 2020 | 1.014M |
| September 30, 2020 | 1.708M |
| June 30, 2020 | 1.656M |
| Date | Value |
|---|---|
| March 31, 2020 | 1.529M |
| December 31, 2019 | 0.4648M |
| September 30, 2019 | 0.4914M |
| June 30, 2019 | 0.517M |
| March 31, 2019 | 0.8706M |
| December 31, 2018 | -0.1449M |
| September 30, 2018 | 1.317M |
| June 30, 2018 | 1.472M |
| March 31, 2018 | 1.282M |
| December 31, 2017 | 1.864M |
| September 30, 2017 | 1.814M |
| June 30, 2017 | 1.358M |
| March 31, 2017 | 1.193M |
| December 31, 2016 | 0.5834M |
| September 30, 2016 | 1.677M |
| June 30, 2016 | 3.400M |
| March 31, 2016 | 2.028M |
| December 31, 2015 | 1.997M |
| September 30, 2015 | 2.112M |
| June 30, 2015 | 1.506M |
| March 31, 2015 | 1.402M |
| December 31, 2014 | 1.920M |
| September 30, 2014 | 1.483M |
| June 30, 2014 | 1.784M |
| March 31, 2014 | 4.330M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Erasca, Inc. | 35.90M |
| Vericel Corp. | 7.493M |
| Emergent BioSolutions, Inc. | 9.20M |
| Exelixis, Inc. | 211.99M |
| Krystal Biotech, Inc. | 13.16M |